Lexicon Pharmaceuticals (LXRX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

LXRX Stock Forecast

Lexicon Pharmaceuticals stock forecast is as follows: an average price target of $6.00 (represents a 677.50% upside from LXRX’s last price of $0.77) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

LXRX Price Target

The average price target for Lexicon Pharmaceuticals (LXRX) is $6.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 677.50% upside from LXRX's last price of $0.77.

LXRX Analyst Ratings

Buy

According to 4 Wall Street analysts, Lexicon Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for LXRX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Lexicon Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 18, 2024	Roanna Ruiz	Leerink Partners	$6.00	$2.01	198.51%	677.50%

Row per page

Go to

The latest Lexicon Pharmaceuticals stock forecast, released on Oct 18, 2024 by Roanna Ruiz from Leerink Partners, set a price target of $6.00, which represents a 198.51% increase from the stock price at the time of the forecast ($2.01), and a 677.50% increase from LXRX last price ($0.77).

Lexicon Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	1
Avg Price Target	-	$6.00	$6.00
Last Closing Price	$0.77	$0.77	$0.77
Upside/Downside	-100.00%	677.50%	677.50%

In the current month, the average price target of Lexicon Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lexicon Pharmaceuticals's last price of $0.77. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 23, 2024	H.C. Wainwright	Buy	Buy	Hold
Oct 18, 2024	Leerink Partners	Outperform	Outperform	Hold
Oct 17, 2024	Piper Sandler	Overweight	Overweight	Hold
Sep 27, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 03, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 02, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 17, 2024	H.C. Wainwright	-	Buy	Initialise
May 31, 2024	Piper Sandler	Overweight	Overweight	Hold
Jul 01, 2022	Citigroup	Buy	Buy	Hold

Row per page

Go to

Lexicon Pharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 23, 2024. The company gave LXRX a "Buy" rating, the same as its previous rate.

Lexicon Pharmaceuticals Financial Forecast

Lexicon Pharmaceuticals Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$702.00K	$162.00K	$317.00K	$24.00K	$28.00K	$39.00K	$35.00K	$37.00K	$234.00K	$27.00K	$199.00K	$6.63M	$9.16M	$8.00M	$8.73M	$294.45M	$9.68M	$9.22M
Avg Forecast	$20.95M	$25.26M	$19.88M	$18.03M	$13.41M	$9.30M	$6.09M	$4.23M	$7.28M	$2.99M	$3.44M	$1.40M	$1.25M	$2.06M	$66.67K	$33.33K	$50.00K	$50.00K	$100.00K	$50.00K	$13.50K	$2.23M	$66.67K	$91.34M	$8.84M	$7.78M	$10.26M	$12.00M	$28.52M	$13.29M
High Forecast	$55.15M	$66.51M	$52.35M	$47.48M	$35.31M	$24.50M	$16.05M	$4.45M	$23.18M	$7.88M	$3.44M	$3.69M	$1.40M	$2.06M	$175.53K	$87.76K	$131.65K	$50.00K	$100.00K	$50.00K	$13.50K	$2.23M	$66.67K	$91.34M	$8.84M	$7.78M	$10.26M	$12.00M	$28.52M	$13.29M
Low Forecast	$10.42M	$12.57M	$9.89M	$8.97M	$6.67M	$4.63M	$3.03M	$4.00M	$1.70M	$1.49M	$3.44M	$696.58K	$1.10M	$2.06M	$33.17K	$16.59K	$24.88K	$50.00K	$100.00K	$50.00K	$13.50K	$2.23M	$66.67K	$91.34M	$8.84M	$7.78M	$10.26M	$12.00M	$28.52M	$13.29M
# Analysts	1	1	1	1	1	1	1	2	5	4	1	1	3	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.56%	0.08%	4.75%	0.72%	0.56%	0.78%	0.35%	0.74%	17.33%	0.01%	2.98%	0.07%	1.04%	1.03%	0.85%	24.55%	0.34%	0.69%

Lexicon Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.40M, with a low forecast of $696.58K, and a high forecast of $3.69M. LXRX's average Quarter revenue forecast represents a 99.43% increase compared to the company's last Quarter revenue of $702.00K (Dec 23).

Lexicon Pharmaceuticals EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	1	1	1	2	5	4	1	1	3	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-46.74M	$-49.63M	$-44.24M	$-30.11M	$-29.39M	$-22.41M	$-23.88M	$-23.26M	$-17.86M	$-20.75M	$-4.98M	$87.50M	$-63.05M	$-60.57M	$-45.01M	$226.18M	$-16.94M	$-15.78M
Avg Forecast	$-14.50M	$-17.48M	$-13.76M	$-12.48M	$-9.28M	$-6.44M	$-4.22M	$-2.92M	$-5.04M	$-2.07M	$-2.38M	$-20.33M	$-865.72K	$-1.43M	$-46.14K	$-21.75M	$-24.99M	$-34.62K	$-69.23K	$-23.26M	$-9.35K	$-22.05M	$-46.15K	$-63.23M	$-6.12M	$-65.84M	$-7.11M	$-8.30M	$-19.74M	$-16.50M
High Forecast	$-7.21M	$-8.70M	$-6.85M	$-6.21M	$-4.62M	$-3.20M	$-2.10M	$-2.77M	$-1.18M	$-1.03M	$-2.38M	$-16.27M	$-763.87K	$-1.43M	$-22.96K	$-17.40M	$-19.99M	$-34.62K	$-69.23K	$-18.61M	$-9.35K	$-17.64M	$-46.15K	$-63.23M	$-6.12M	$-52.67M	$-7.11M	$-8.30M	$-19.74M	$-13.20M
Low Forecast	$-38.17M	$-46.03M	$-36.23M	$-32.86M	$-24.44M	$-16.96M	$-11.11M	$-3.08M	$-16.04M	$-5.45M	$-2.38M	$-24.40M	$-967.57K	$-1.43M	$-121.49K	$-26.09M	$-29.98M	$-34.62K	$-69.23K	$-27.91M	$-9.35K	$-26.46M	$-46.15K	$-63.23M	$-6.12M	$-79.01M	$-7.11M	$-8.30M	$-19.74M	$-19.80M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	53.99%	34.81%	958.80%	1.38%	1.18%	647.55%	344.99%	1.00%	1910.55%	0.94%	107.92%	-1.38%	10.31%	0.92%	6.33%	-27.24%	0.86%	0.96%

9 analysts predict LXRX's average Quarter EBITDA for Dec 20 to be $-46.15K, with a high of $-46.15K and a low of $-46.15K. This is -100.05% lower than Lexicon Pharmaceuticals's previous annual EBITDA (Sep 20) of $87.50M.

Lexicon Pharmaceuticals Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	1	1	1	2	5	4	1	1	3	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-48.24M	$-50.52M	$-44.90M	$-30.91M	$-30.71M	$-23.68M	$-25.17M	$-23.57M	$-18.07M	$-20.96M	$-5.50M	$82.60M	$-69.07M	$-66.61M	$-51.14M	$226.09M	$-23.02M	$-21.80M
Avg Forecast	$-61.45M	$-57.84M	$-57.84M	$-57.84M	$-50.61M	$-54.22M	$-54.22M	$-54.22M	$-45.55M	$-58.87M	$-63.98M	$-20.52M	$-78.51M	$-77.60M	$-63.13M	$-21.95M	$-25.28M	$-43.54M	$-50.08M	$-23.48M	$-49.63M	$-22.27M	$-85.98M	$114.10M	$-188.88M	$-72.40M	$-239.79M	$-69.94M	$-29.76M	$-22.79M
High Forecast	$-21.31M	$-20.06M	$-20.06M	$-20.06M	$-17.55M	$-18.81M	$-18.81M	$-46.99M	$-24.53M	$-20.42M	$-22.19M	$-16.42M	$-71.68M	$-26.91M	$-21.90M	$-17.56M	$-20.22M	$-43.54M	$-50.08M	$-18.78M	$-49.63M	$-17.81M	$-85.98M	$114.10M	$-188.88M	$-57.92M	$-239.79M	$-69.94M	$-29.76M	$-18.23M
Low Forecast	$-191.91M	$-180.62M	$-180.62M	$-180.62M	$-158.04M	$-169.33M	$-169.33M	$-61.45M	$-56.06M	$-183.83M	$-199.79M	$-24.63M	$-81.92M	$-242.33M	$-197.16M	$-26.34M	$-30.33M	$-43.54M	$-50.08M	$-28.17M	$-49.63M	$-26.72M	$-85.98M	$114.10M	$-188.88M	$-86.88M	$-239.79M	$-69.94M	$-29.76M	$-27.35M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.61%	0.65%	0.71%	1.41%	1.21%	0.54%	0.50%	1.00%	0.36%	0.94%	0.06%	0.72%	0.37%	0.92%	0.21%	-3.23%	0.77%	0.96%

Lexicon Pharmaceuticals's average Quarter net income forecast for Dec 20 is $-85.98M, with a range of $-85.98M to $-85.98M. LXRX's average Quarter net income forecast represents a -204.08% decrease compared to the company's last Quarter net income of $82.60M (Sep 20).

Lexicon Pharmaceuticals SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	1	1	1	2	5	4	1	1	3	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$32.61M	$32.23M	$30.01M	$19.14M	$16.33M	$12.58M	$10.69M	$8.49M	$7.94M	$8.26M	$6.43M	$12.00M	$14.11M	$14.69M	$14.56M	$13.90M	$14.26M	$14.11M
Avg Forecast	$2.31B	$2.78B	$2.19B	$1.99B	$1.48B	$1.03B	$671.88M	$465.87M	$802.11M	$330.02M	$378.78M	$154.35M	$137.91M	$227.14M	$7.35M	$3.68M	$5.51M	$5.51M	$11.03M	$5.51M	$1.49M	$246.42M	$7.35M	$10.07B	$974.09M	$858.04M	$1.13B	$1.32B	$3.14B	$1.47B
High Forecast	$6.08B	$7.33B	$5.77B	$5.23B	$3.89B	$2.70B	$1.77B	$490.10M	$2.56B	$868.94M	$378.81M	$406.41M	$154.13M	$227.15M	$19.35M	$9.68M	$14.51M	$5.51M	$11.03M	$5.51M	$1.49M	$246.42M	$7.35M	$10.07B	$974.09M	$858.04M	$1.13B	$1.32B	$3.14B	$1.47B
Low Forecast	$1.15B	$1.39B	$1.09B	$989.19M	$735.78M	$510.45M	$334.30M	$440.54M	$187.19M	$164.21M	$378.76M	$76.80M	$121.68M	$227.13M	$3.66M	$1.83M	$2.74M	$5.51M	$11.03M	$5.51M	$1.49M	$246.42M	$7.35M	$10.07B	$974.09M	$858.04M	$1.13B	$1.32B	$3.14B	$1.47B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.24%	0.14%	4.08%	5.21%	2.96%	2.28%	0.97%	1.54%	5.33%	0.03%	0.88%	0.00%	0.01%	0.02%	0.01%	0.01%	0.00%	0.01%

Lexicon Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $154.35M, based on 1 Wall Street analysts, with a range of $76.80M to $406.41M. The forecast indicates a 373.38% rise compared to LXRX last annual SG&A of $32.61M (Dec 23).

Lexicon Pharmaceuticals EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	1	1	1	2	5	4	1	1	3	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.20	$-0.21	$-0.22	$-0.16	$-0.16	$-0.14	$-0.17	$-0.16	$-0.13	$-0.15	$-0.04	$0.77	$-0.65	$-0.63	$-0.48	$2.13	$-0.22	$-0.21
Avg Forecast	$-0.17	$-0.16	$-0.16	$-0.16	$-0.14	$-0.15	$-0.15	$-0.15	$-0.13	$-0.16	$-0.18	$-0.18	$-0.22	$-0.21	$-0.17	$-0.18	$-0.13	$-0.14	$-0.16	$-0.17	$-0.16	$-0.16	$-0.28	$0.37	$-0.61	$-0.69	$-0.77	$-0.23	$-0.10	$-0.22
High Forecast	$-0.06	$-0.06	$-0.06	$-0.06	$-0.05	$-0.05	$-0.05	$-0.13	$-0.07	$-0.06	$-0.06	$-0.06	$-0.20	$-0.07	$-0.06	$-0.06	$-0.05	$-0.14	$-0.16	$-0.17	$-0.16	$-0.16	$-0.28	$0.37	$-0.61	$-0.69	$-0.77	$-0.23	$-0.10	$-0.22
Low Forecast	$-0.53	$-0.50	$-0.50	$-0.50	$-0.44	$-0.47	$-0.47	$-0.17	$-0.16	$-0.51	$-0.55	$-0.56	$-0.23	$-0.67	$-0.55	$-0.56	$-0.42	$-0.14	$-0.16	$-0.17	$-0.16	$-0.16	$-0.28	$0.37	$-0.61	$-0.69	$-0.77	$-0.23	$-0.10	$-0.22
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.92%	0.98%	1.26%	0.89%	1.20%	1.00%	1.06%	0.97%	0.81%	0.95%	0.14%	2.10%	1.07%	0.91%	0.62%	-9.47%	2.30%	0.94%

According to 9 Wall Street analysts, Lexicon Pharmaceuticals's projected average Quarter EPS for Dec 20 is $-0.28, with a low estimate of $-0.28 and a high estimate of $-0.28. This represents a -135.92% decrease compared to LXRX previous annual EPS of $0.77 (Sep 20).

Lexicon Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.69	$70.00	10044.93%	Buy
ELEV	Elevation Oncology	$0.61	$9.00	1375.41%	Buy
XFOR	X4 Pharmaceuticals	$0.37	$3.67	891.89%	Buy
LXRX	Lexicon Pharmaceuticals	$0.77	$6.00	679.22%	Buy
DAWN	Day One Biopharmaceuticals	$13.34	$38.80	190.85%	Buy
TERN	Terns Pharmaceuticals	$5.71	$14.25	149.56%	Buy
MREO	Mereo BioPharma Group	$3.68	$6.75	83.42%	Buy
MCRB	Seres Therapeutics	$0.73	$1.25	71.23%	Buy
ARDX	Ardelyx	$5.12	$8.75	70.90%	Buy
IBRX	ImmunityBio	$5.04	$8.00	58.73%	Buy
HOOK	HOOKIPA Pharma	$2.30	$3.00	30.43%	Buy
EFTR	eFFECTOR Therapeutics	-	$5.50	-	Buy

LXRX Forecast FAQ

Is Lexicon Pharmaceuticals a good buy?

Yes, according to 4 Wall Street analysts, Lexicon Pharmaceuticals (LXRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of LXRX's total ratings.

What is LXRX's price target?

Lexicon Pharmaceuticals (LXRX) average price target is $6 with a range of $6 to $6, implying a 677.50% from its last price of $0.772. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Lexicon Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for LXRX stock, the company can go up by 677.50% (from the last price of $0.772 to the average price target of $6), up by 677.50% based on the highest stock price target, and up by 677.50% based on the lowest stock price target.

Can Lexicon Pharmaceuticals stock reach $1?

LXRX's average twelve months analyst stock price target of $6 supports the claim that Lexicon Pharmaceuticals can reach $1 in the near future.

What are Lexicon Pharmaceuticals's analysts' financial forecasts?

Lexicon Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $33.04M (high $80.3M, low $18.33M), average EBITDA is $-22.865M (high $-12.687M, low $-55.58M), average net income is $-213M (high $-102M, low $-558M), average SG&A $3.64B (high $8.85B, low $2.02B), and average EPS is $-0.59 (high $-0.283, low $-1.544). LXRX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $84.12M (high $221.48M, low $41.85M), average EBITDA is $-58.22M (high $-28.968M, low $-153M), average net income is $-235M (high $-81.494M, low $-734M), average SG&A $9.27B (high $24.42B, low $4.61B), and average EPS is $-0.65 (high $-0.225, low $-2.03).

Did the LXRX's actual financial results beat the analysts' financial forecasts?

Based on Lexicon Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $1.2M, which missed the average analysts forecast of $3.41M by -64.70%. Apple's EBITDA was $-172M, beating the average prediction of $-24.083M by 613.16%. The company's net income was $-176M, missing the average estimation of $-241M by -27.19%. Apple's SG&A was $113.98M, missing the average forecast of $376.08M by -69.69%. Lastly, the company's EPS was $-0.79, beating the average prediction of $-0.786 by 0.53%. In terms of the last quarterly report (Dec 2023), Lexicon Pharmaceuticals's revenue was $702K, missing the average analysts' forecast of $1.25M by -43.88%. The company's EBITDA was $-46.737M, beating the average prediction of $-866K by 5298.61%. Lexicon Pharmaceuticals's net income was $-48.244M, missing the average estimation of $-78.505M by -38.55%. The company's SG&A was $32.61M, missing the average forecast of $137.91M by -76.36%. Lastly, the company's EPS was $-0.2, missing the average prediction of $-0.217 by -7.91%